Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study.
10.5213/inj.2015.19.2.107
- Author:
Sung Gon PARK
1
;
Byung Ha CHUNG
;
Sung Won LEE
;
Jong Kwan PARK
;
Kwangsung PARK
;
Jun CHEON
;
Kyung Seop LEE
;
Hyung Jee KIM
;
Do Hwan SEONG
;
Seung June OH
;
Sae Woong KIM
;
Ji Youl LEE
;
Seol Ho CHOO
;
Jong Bo CHOI
Author Information
1. Department of Urology, Ajou University School of Medicine, Suwon, Korea. predoc@naver.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Heart Rate;
Prostatic Hyperplasia;
Sympathetic Nervous System;
Lower Urinary Tract Symptoms
- MeSH:
Drug-Related Side Effects and Adverse Reactions;
Heart;
Heart Rate;
Humans;
Lower Urinary Tract Symptoms*;
Male;
Observational Study*;
Prospective Studies*;
Prostate;
Prostatic Hyperplasia;
Quality of Life;
Sympathetic Nervous System
- From:International Neurourology Journal
2015;19(2):107-112
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: In this study, we compared the treatment outcomes for an alpha-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. METHODS: A total of 159 men (> or =50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart ratevariability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate SymptomScore (IPSS) at 12 weeks from baseline. RESULTS: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. Themean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. TheHSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. CONCLUSIONS: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.
